Entera Bio Ltd (ENTX)
NASDAQ:ENTX
Top Page
Entera Bio
(NASDAQ:ENTX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.00
▼(-2.91% Downside)
Action:ReiteratedDate:02/04/26
The score is held back primarily by weak financial performance (minimal/declining revenue, persistent losses, and cash burn) and bearish technicals (below major moving averages with negative MACD). Offsetting support comes from low leverage/improved equity and positive corporate developments (expanded OPKO collaboration and FDA Phase 3 agreement), while valuation signals are limited due to negative earnings and no dividend.
Positive Factors
Strategic partnership expansion
The expanded OPKO collaboration creates durable R&D and funding capacity by sharing 50% ownership and development costs for the LA‑PTH program. Joint ownership aligns incentives, reduces Entera’s single‑party cash burden, and accelerates development scale and regulatory readiness over the next 2–6 months and beyond.
Negative Factors
Minimal and declining revenue
Persistent minimal revenue emphasizes Entera’s current reliance on R&D milestones and partnerships rather than product sales. Over the next several quarters this limits internal cash generation, increases dependency on external funding or alliances, and raises execution risk if trials delay or partnerships change.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic partnership expansion
The expanded OPKO collaboration creates durable R&D and funding capacity by sharing 50% ownership and development costs for the LA‑PTH program. Joint ownership aligns incentives, reduces Entera’s single‑party cash burden, and accelerates development scale and regulatory readiness over the next 2–6 months and beyond.
Read all positive factors
Entera Bio (ENTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$47.23M
Dividend YieldN/A
Average Volume (3M)123.78K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue Growth25.25%
EPS Growth5.96%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.07
Shares Outstanding45,857,243
10 Day Avg. Volume240,874
30 Day Avg. Volume123,776
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)9.88
Price to Sales (P/S)440.99
P/FCF Ratio-11.70
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue313.47
Enterprise Value/Gross Profit-4.86K
Enterprise Value/Ebitda-3.62
Forecast
1Y Price Target
$10.00Price Target Upside870.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$54.58M
Entera Bio Business Overview & Revenue Model
Company Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which i...
How the Company Makes Money
Entera Bio generates revenue through the development and commercialization of its proprietary oral drug formulations. The company's key revenue streams include collaborations and licensing agreements with other pharmaceutical companies. These part...
Entera Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
63
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 124.00K | 181.00K | 0.00 | 134.00K | 571.00K | 365.00K |
| Gross Profit | -8.00K | 9.00K | -56.00K | -31.00K | 198.00K | 65.00K |
| EBITDA | -10.73M | -9.54M | -8.80M | -12.87M | -12.16M | -11.11M |
| Net Income | -10.78M | -9.54M | -8.89M | -13.07M | -12.19M | -11.22M |
Balance Sheet | ||||||
| Total Assets | 17.41M | 9.39M | 11.77M | 13.13M | 25.99M | 9.72M |
| Cash, Cash Equivalents and Short-Term Investments | 8.57M | 8.66M | 11.02M | 12.31M | 24.89M | 8.59M |
| Total Debt | 211.00K | 272.00K | 390.00K | 91.00K | 302.00K | 432.00K |
| Total Liabilities | 2.17M | 1.31M | 1.38M | 1.37M | 3.42M | 2.21M |
| Stockholders Equity | 15.23M | 8.08M | 10.39M | 11.75M | 22.57M | 7.51M |
Cash Flow | ||||||
| Free Cash Flow | -7.34M | -6.82M | -7.33M | -12.55M | -9.08M | -10.61M |
| Operating Cash Flow | -7.26M | -6.82M | -7.31M | -12.50M | -9.06M | -10.56M |
| Investing Cash Flow | -86.65K | -3.00K | -17.00K | -102.00K | -17.00K | -53.00K |
| Financing Cash Flow | 17.37M | 4.48M | 6.04M | 13.00K | 25.38M | 4.05M |
Entera Bio Technical Analysis
Negative
1.03
Price Trends
1.40
Negative
1.85
Negative
1.92
Negative
Market Momentum
-0.09
Positive
33.44
Neutral
11.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENTX, the sentiment is Negative. The current price of 1.03 is below the 20-day moving average (MA) of 1.31, below the 50-day MA of 1.40, and below the 200-day MA of 1.92, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 33.44 is Neutral, neither overbought nor oversold. The STOCH value of 11.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENTX.
Entera Bio Risk Analysis
Entera Bio disclosed 72 risk factors in its most recent earnings report. Entera Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Entera Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $123.00M | -3.02 | -148.81% | ― | -90.43% | -382.07% | |
49 Neutral | $70.43M | -2.03 | 138.71% | ― | ― | -9.32% | |
49 Neutral | $79.87M | -0.50 | -69.56% | ― | ― | 14.19% | |
47 Neutral | $47.23M | -7.06 | -99.43% | ― | 25.25% | 5.96% | |
44 Neutral | $81.13M | -0.98 | -99.62% | ― | -19.15% | 10.90% |
* Healthcare Sector Average
ENTX
Entera Bio
1.03
-0.85
-45.21%
ATYR
aTyr Pharma
0.79
-2.70
-77.39%
NRXP
NRX Pharmaceuticals
2.13
0.12
5.97%
EQ
Equillium
1.95
1.15
143.75%
PLRX
Pliant Therapeutics
1.28
-0.21
-14.09%
Entera Bio Corporate Events
Business Operations and StrategyExecutive/Board Changes
Entera Bio Expands OPKO Partnership, Adds New Director
Positive
Feb 4, 2026
On February 3, 2026, Entera Bio and OPKO Health broadened their 2025 collaboration and license agreement to add joint preclinical and clinical development of a once-daily long-acting PTH (LA-PTH) oral tablet for hypoparathyroidism and other indica...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Entera Bio Reports Q3 2025 Results and FDA Agreement
Positive
Nov 14, 2025
Entera Bio announced its third quarter 2025 financial results and business updates, highlighting significant progress in its oral peptide therapies. The company received FDA agreement for its EB613 Phase 3 study, marking a pivotal step in osteopor...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.